Zacks Research Lifts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research upped their Q1 2026 earnings estimates for shares of Globus Medical in a note issued to investors on Tuesday, March 10th. Zacks Research analyst Team now expects that the medical device company will earn $0.88 per share for the quarter, up from their previous estimate of $0.80. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $1.02 EPS, Q3 2026 earnings at $1.13 EPS, Q4 2027 earnings at $1.23 EPS and FY2028 earnings at $5.18 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.During the same quarter in the previous year, the company posted $0.84 earnings per share. The business’s revenue for the quarter was up 25.7% compared to the same quarter last year.

Other research analysts have also issued research reports about the company. Truist Financial set a $115.00 price target on Globus Medical in a research report on Wednesday, February 25th. Morgan Stanley lifted their price objective on shares of Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group upped their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, January 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Finally, Royal Bank Of Canada raised their target price on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Globus Medical Price Performance

GMED opened at $87.22 on Wednesday. The stock’s 50 day moving average price is $90.82 and its 200 day moving average price is $78.05. The stock has a market cap of $11.80 billion, a P/E ratio of 22.14, a P/E/G ratio of 2.02 and a beta of 1.05. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40.

Institutional Trading of Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Corient Private Wealth LLC grew its position in Globus Medical by 7.1% in the fourth quarter. Corient Private Wealth LLC now owns 51,372 shares of the medical device company’s stock worth $4,487,000 after buying an additional 3,390 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Globus Medical during the 4th quarter valued at $2,254,000. MidFirst Bank bought a new stake in shares of Globus Medical during the 4th quarter worth $354,000. Pacer Advisors Inc. boosted its stake in shares of Globus Medical by 20.4% during the 4th quarter. Pacer Advisors Inc. now owns 33,177 shares of the medical device company’s stock worth $2,897,000 after acquiring an additional 5,617 shares in the last quarter. Finally, Kera Capital Partners Inc. acquired a new position in shares of Globus Medical in the 4th quarter worth $202,000. 95.16% of the stock is currently owned by institutional investors.

Insider Activity at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of Globus Medical stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the transaction, the director directly owned 10,419 shares of the company’s stock, valued at $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 35,594 shares of company stock valued at $3,332,253 over the last 90 days. 18.51% of the stock is currently owned by corporate insiders.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across Q1–Q4 (2026–2027) and issued an FY2028 projection of $5.18, maintaining a “Strong‑Buy” rating — this boosts earnings credibility and upside expectations.
• Positive Sentiment: Short interest dropped ~30% in February to ~3.27M shares (≈3.0% of float), lowering potential selling pressure and shortening the days‑to‑cover to about 2.3 days — a constructive technical development.
• Positive Sentiment: Q4 results and Nevro update refreshed the investment story: Q4 revenue and EPS beats support the raised estimates and near‑term momentum. How The Globus Medical (GMED) Investment Story Is Evolving After Q4 Results And Nevro Update
• Positive Sentiment: GMED was included in a Zacks list of 5 medical instruments stocks with short‑term upside, highlighting favorable analyst attention and thematic tailwinds (AI, M&A, product pipeline). 5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
• Neutral Sentiment: The company reaffirmed its 2026 outlook, prompting discussion about capital allocation priorities (share repurchases vs. M&A/investment) — signals stability but decisions will drive long‑term allocation impact. Does Globus Medical’s (GMED) Reaffirmed 2026 Outlook Reveal Its Next Capital Allocation Priorities?
• Neutral Sentiment: Analysts and value models are reassessing fair value after recent share weakness—this has generated more coverage and volatility but not new negative company fundamentals. Assessing Globus Medical (GMED) After Recent Share Price Weakness And Fair Value Signals

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.